Next Article in Journal
Glycosylation in the Tumor Microenvironment: Implications for Tumor Angiogenesis and Metastasis
Next Article in Special Issue
CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis
Previous Article in Journal
Recent Data on Cellular Component Turnover: Focus on Adaptations to Physical Exercise
Previous Article in Special Issue
Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis Patients
Open AccessReview

Nanomodulation of Macrophages in Multiple Sclerosis

Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St Stephen’s Green, 2 D02 YN77 Dublin, Ireland
*
Author to whom correspondence should be addressed.
Cells 2019, 8(6), 543; https://doi.org/10.3390/cells8060543
Received: 15 May 2019 / Revised: 31 May 2019 / Accepted: 3 June 2019 / Published: 5 June 2019
(This article belongs to the Special Issue The Molecular and Cellular Basis for Multiple Sclerosis)
Multiple Sclerosis (MS) is a chronic demyelinating autoimmune disease primarily affecting young adults. Despite an unclear causal factor, symptoms and pathology arise from the infiltration of peripheral immune cells across the blood brain barrier. Accounting for the largest fraction of this infiltrate, macrophages are functionally heterogeneous innate immune cells capable of adopting either a pro or an anti-inflammatory phenotype, a phenomenon dependent upon cytokine milieu in the CNS. This functional plasticity is of key relevance in MS, where the pro-inflammatory state dominates the early stage, instructing demyelination and axonal loss while the later anti-inflammatory state holds a key role in promoting tissue repair and regeneration in later remission. This review highlights a potential therapeutic benefit of modulating macrophage polarisation to harness the anti-inflammatory and reparative state in MS. Here, we outline the role of macrophages in MS and look at the role of current FDA approved therapeutics in macrophage polarisation. Moreover, we explore the potential of particulate carriers as a novel strategy to manipulate polarisation states in macrophages, whilst examining how optimising macrophage uptake via nanoparticle size and functionalisation could offer a novel therapeutic approach for MS. View Full-Text
Keywords: multiple sclerosis; experimental autoimmune encephalomyelitis; macrophage polarisation; monocytes; microglia; inflammation; nanoparticle; microparticle; drug delivery; CNS multiple sclerosis; experimental autoimmune encephalomyelitis; macrophage polarisation; monocytes; microglia; inflammation; nanoparticle; microparticle; drug delivery; CNS
Show Figures

Figure 1

MDPI and ACS Style

Nally, F.K.; De Santi, C.; McCoy, C.E. Nanomodulation of Macrophages in Multiple Sclerosis. Cells 2019, 8, 543.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop